Letter to Utah Congressional Delegation RE: H.R. 3, The Lower Drug Costs Now Act
May 25, 2021
Today, BioUtah, in conjunction with Centro Civico Mexicano, First Step House, International Cancer Advocacy Network, Mental Healthy FIT, Northern Utah Coalition, and Patel Family Investments, sent a letter to Utah’s congressional delegation expressing concern with the reintroduction of H.R. 3, The Lower Drug Costs Now Act. In the letter, the coalition states its concern about the bill’s negative impact on investment in drug discovery.
You may read the letter in its entirety here.
Recent News
- Nucleus Institute Convergence Point Groundbreaking
- EDWARDS LIFESCIENCES RECEIVES FDA APPROVAL FOR AUTUS VALVE
- Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
- Owlet Announces Creation of Baby Safety Task Force to Educate, Innovate, and Advocate for Better Baby Safety Standards
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
